Q4 2023 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2024-02-14 · accession 0001104659-24-024053
$8.79B
Reported value
84
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45337C102 | INCY | Incyte Corporation | $2.27B | 25.8% | 36,179,122 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $1.91B | 21.7% | 10,568,897 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $1.34B | 15.3% | 42,864,612 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $455.8M | 5.19% | 1,969,798 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $294.1M | 3.35% | 6,398,365 | Common | SOLE |
| 60468T105 | MRTXEUR | Mirati Therapeutics, Inc. | $242.1M | 2.76% | 4,121,440 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $172.2M | 1.96% | 2,520,731 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $152.7M | 1.74% | 5,995,928 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $147.7M | 1.68% | 5,148,657 | Common | SOLE |
| 46185LAD5 | — | Invitae Corporation | $131.2M | 1.49% | 300,000,000 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $130.8M | 1.49% | 22,909,753 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $85.3M | 0.97% | 7,593,024 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $80.5M | 0.92% | 9,545,336 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $73.4M | 0.84% | 4,865,819 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $70.1M | 0.80% | 1,466,547 | Common | SOLE |
| 15678U128 | CERE1EUR | Cerevel Therapeutics Holdings, Inc. | $67.8M | 0.77% | 1,600,000 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $61.5M | 0.70% | 5,838,853 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $60.7M | 0.69% | 10,126,176 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $57.5M | 0.65% | 151,215 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $56.0M | 0.64% | 2,607,196 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $55.3M | 0.63% | 2,368,378 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $52.6M | 0.60% | 17,310,490 | Common | SOLE |
| G5269C101 | — | Kiniksa Pharmaceuticals, Ltd. | $49.3M | 0.56% | 2,809,577 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $45.8M | 0.52% | 993,679 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $43.2M | 0.49% | 10,123,824 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $42.1M | 0.48% | 19,477,339 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $40.1M | 0.46% | 3,882,125 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $38.0M | 0.43% | 1,680,517 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $37.8M | 0.43% | 1,062,123 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $34.1M | 0.39% | 3,112,786 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $32.5M | 0.37% | 5,434,399 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $32.4M | 0.37% | 1,790,390 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $30.7M | 0.35% | 3,691,011 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $30.6M | 0.35% | 2,108,949 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $27.8M | 0.32% | 4,916,095 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $23.6M | 0.27% | 1,691,530 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $21.1M | 0.24% | 169,934 | Common | SOLE |
| 38406L103 | — | Gracell Biotechnologies Inc. | $20.9M | 0.24% | 2,080,000 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $17.9M | 0.20% | 425,009 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $16.2M | 0.18% | 2,784,792 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $14.6M | 0.17% | 1,000,000 | Common | SOLE |
| 23306J101 | — | DBV Technologies S.A. | $13.9M | 0.16% | 14,614,264 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $12.8M | 0.15% | 1,160,117 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $11.0M | 0.13% | 2,006,451 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $10.7M | 0.12% | 2,030,134 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $10.7M | 0.12% | 2,497,526 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $10.6M | 0.12% | 343,000 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $9.8M | 0.11% | 247,644 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $9.1M | 0.10% | 1,028,466 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $8.8M | 0.10% | 453,516 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $8.7M | 0.10% | 10,969,282 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $8.2M | 0.09% | 2,000,000 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $7.9M | 0.09% | 1,456,518 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $7.8M | 0.09% | 535,478 | Common | SOLE |
| 04746L104 | — | Athira Pharma, Inc. | $7.7M | 0.09% | 3,153,807 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $7.6M | 0.09% | 2,588,645 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $7.4M | 0.08% | 750,000 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $7.1M | 0.08% | 4,004,756 | Common | SOLE |
| 43906K100 | HOOKGBP | HOOKIPA Pharma Inc. | $6.6M | 0.07% | 8,128,151 | Common | SOLE |
| 46185LAH6 | — | Invitae Corporation | $6.3M | 0.07% | 9,274,000 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $5.6M | 0.06% | 190,476 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $5.2M | 0.06% | 245,431 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $4.9M | 0.06% | 1,172,175 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $4.0M | 0.05% | 1,500,000 | Common | SOLE |
| 87424L207 | TLIS | Talis Biomedical Corporation | $3.8M | 0.04% | 508,323 | Common | SOLE |
| 46489V104 | ISREUR | Perspective Therapeutics, Inc. | $3.1M | 0.03% | 7,639,703 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $3.1M | 0.03% | 48,885 | Common | SOLE |
| 74006W108 | — | Praxis Precision Medicines, Inc. | $2.9M | 0.03% | 131,533 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $2.6M | 0.03% | 797,460 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $2.5M | 0.03% | 1,086,115 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $2.4M | 0.03% | 1,557,630 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics plc | $1.9M | 0.02% | 2,102,792 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $1.9M | 0.02% | 266,613 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics, Inc. | $1.4M | 0.02% | 2,076,400 | Common | SOLE |
| 46185L103 | NVTA1EUR | Invitae Corporation | $1.1M | 0.01% | 1,764,546 | Common | SOLE |
| 717081103 | PFE | Pfizer Inc. | $1.0M | 0.01% | 35,000 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $998,274 | 0.01% | 322,024 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience, Inc. | $508,489 | 0.01% | 251,727 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $374,403 | 0.00% | 199,671 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio, Inc. | $302,614 | 0.00% | 13,331 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $290,424 | 0.00% | 45,027 | Common | SOLE |
| 04965G109 | BCELUSD | Atreca, Inc. | $287,430 | 0.00% | 2,177,499 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $146,907 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $16,167 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.